Isabelle Duplan
Overview
Explore the profile of Isabelle Duplan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andres M, Hennuyer N, Zibar K, Bicharel-Leconte M, Duplan I, Enee E, et al.
Br J Pharmacol
. 2024 May;
181(19):3610-3626.
PMID: 38812293
Background And Purpose: Nonalcoholic fatty liver disease refers to liver pathologies, ranging from steatosis to steatohepatitis, with fibrosis ultimately leading to cirrhosis and hepatocellular carcinoma. Although several mechanisms have been...
2.
Garcia A, Vila L, Duplan I, Schiel M, Enriz R, Hennuyer N, et al.
Eur J Med Chem
. 2024 Jan;
265:116125.
PMID: 38185055
Peroxisome proliferator-activated receptors (PPARs) play a major role in regulating inflammatory processes, and dual or pan-PPAR agonists with PPARγ partial activation have been recognised to be useful to manage both...
3.
Picon S, Boulahjar R, Hoguet V, Baron M, Duplan I, Vallez E, et al.
J Med Chem
. 2023 Aug;
66(17):11732-11760.
PMID: 37639383
A novel series of potent agonists of the bile acid receptor TGR5 bearing a dihydropyridone scaffold was developed from a high-throughput screen. Starting from a micromolar hit compound, we implemented...
4.
Marques P, Villarroel-Vicente C, Collado A, Garcia A, Vila L, Duplan I, et al.
Pharmacol Res
. 2022 Dec;
187:106638.
PMID: 36586645
Background And Purpose: Selective peroxisome proliferator-activated receptors (PPARs) are widely used to treat metabolic complications; however, the limited effect of PPARα agonists on glucose metabolism and the adverse effects associated...
5.
Kraupner N, Dinh C, Wen X, Landry V, Herledan A, Leroux F, et al.
Eur J Med Chem
. 2021 Nov;
228:113982.
PMID: 34815130
Insulin degrading enzyme (IDE) is a zinc metalloprotease that cleaves numerous substrates among which amyloid-β and insulin. It has been linked through genetic studies to the risk of type-2 diabetes...
6.
Hoguet V, Lasalle M, Maingot M, Dequirez G, Boulahjar R, Leroux F, et al.
J Med Chem
. 2021 Jan;
64(3):1593-1610.
PMID: 33470812
PEGylation of therapeutic agents is known to improve the pharmacokinetic behavior of macromolecular drugs and nanoparticles. In this work, we performed the conjugation of polyethylene glycols (220-5000 Da) to a...
7.
Lasalle M, Hoguet V, Hennuyer N, Leroux F, Piveteau C, Belloy L, et al.
J Med Chem
. 2017 Apr;
60(10):4185-4211.
PMID: 28414465
The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising...
8.
Bosviel R, Joumard-Cubizolles L, Chinetti-Gbaguidi G, Bayle D, Copin C, Hennuyer N, et al.
Free Radic Biol Med
. 2016 Dec;
103:146-154.
PMID: 27988338
Whereas the anti-inflammatory properties and mechanisms of action of long chain ω3 PUFAs have been abundantly investigated, research gaps remain regarding the respective contribution and mechanisms of action of their...
9.
Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, et al.
Atherosclerosis
. 2016 Apr;
249:200-8.
PMID: 27108950
Background: Atherosclerosis is characterized by lipid accumulation and chronic inflammation in the arterial wall. Elevated levels of apolipoprotein (apo) B-containing lipoproteins are a risk factor for cardiovascular disease (CVD). By...
10.
Deprez-Poulain R, Hennuyer N, Bosc D, Liang W, Enee E, Marechal X, et al.
Nat Commun
. 2015 Sep;
6:8250.
PMID: 26394692
Insulin-degrading enzyme (IDE) is a protease that cleaves insulin and other bioactive peptides such as amyloid-β. Knockout and genetic studies have linked IDE to Alzheimer's disease and type-2 diabetes. As...